Stellar Pharmaceuticals Inc.
TSX VENTURE : SLX
OTC Bulletin Board : SLXCF

Stellar Pharmaceuticals Inc.

August 10, 2006 08:01 ET

Stellar Pharmaceuticals Announces 2006 Second Quarter Financial Results

Company to Hold Conference Call Today at 11:00 AM ET

LONDON, ONTARIO--(CCNMatthews - Aug. 10, 2006) - Stellar Pharmaceuticals Inc. (TSX VENTURE:SLX)(OTCBB:SLXCF) ("Stellar" or "the Company"), a Canadian pharmaceutical developer and marketer of high quality, cost-effective products for select health care markets, today announced financial results for the second quarter ended June 30, 2006. All amounts in this press release are in Canadian dollars, have been rounded to the nearest thousand, and are the result of the use of U.S. GAAP.

Second Quarter 2006 Review

Total revenues, which include product sales and royalty and licensing revenues, for the three months ended June 30, 2006 were $440,000, as compared to $496,000 in the same period last year. Direct (Canadian) sales of NeoVisc® declined primarily due to the impact of promotional product pricing by two new market entrants. Canadian sales of Uracysta® grew 31.3% during the 2006 second quarter compared to the same period in 2005, largely due to increased sales and marketing efforts. Outlicensed sales of NeoVisc and Uracyst both increased during the second quarter of 2006, as did in-licensed sales of NMP22® BladderChek® ("BladderChek").

Peter Riehl, Stellar's President and CEO, stated, "We are analyzing an array of operational actions, including cost-cutting initiatives, to counter the impact of the evolving viscosupplementation market in Canada. However, we remain confident that over the long-term, Stellar's low-cost, high quality NeoVisc product offers customers the best value per healthcare dollar spent. We are also continuing to identify new niche markets as part of our global licensing strategy. As a result, royalty and licensing revenue should continue to represent a growing percentage of our total sales as approvals are received and sales commence. We commenced sales in two new countries during the second quarter, and in July signed an agreement with BIO-TECHNIC ROMANIA SRL for the distribution of NeoVisc in Romania."

Royalty and licensing revenue increased to $103,000, or 23.4% of total revenues, in the second quarter of 2006 versus $75,000, or 15% of total revenues, for the same period last year, and $89,000 sequentially from the first quarter of 2006.

In the past year, Stellar has announced out-licensing agreements for NeoVisc and Uracyst in Israel, Kuwait, Turkey, Lebanon, China and Romania, giving the Company out-licensing distribution partners in 28 countries. Stellar expects to commence sales in each of these territories as regulatory approvals are granted. Stellar is also continuing to seek out potential new partners for NeoVisc and Uracyst in the United States. The Company has approached, and has been approached by, a number of companies and hopes to continue reaching distribution and licensing agreements that will help to accelerate the growth of these products globally.

BladderChek sales rose during the second quarter of 2006, largely as a result of the implementation of a number of sales initiatives to ease the physician prescription process, which, in turn, have helped to increase the adoption of this product in Canada.

Cost of sales in the second quarter of 2006 was $84,000, or 24.9% of direct sales, versus $92,000, or 21.8% of direct sales, in the second quarter of 2005. This percentage increase was largely due to stability testing for the new higher modular weight of NeoVisc. Selling, general and administrative ("SG&A") expenses in the second quarter of 2006 decreased to $493,000 from $643,000 in the second quarter of 2005; SG&A in the second quarter of fiscal 2006 also declined sequentially from $586,000 in the first quarter of 2006. This decrease came as a result of a number of cost-cutting initiatives, offset by increased costs associated with the pursuit of a European CE mark for NeoVisc and consulting fees related to researching potential U.S. opportunities for NeoVisc and Uracyst. Research and development expenses declined to $68,000 in the 2006 second quarter from $91,000 in the same period last year, which included expenses related to the engineering of a higher molecular weight for NeoVisc.

Stellar's net loss in the second quarter of 2006 narrowed to $232,000, or $0.01 per share, on 23.5 million weighted average common shares outstanding ("shares outstanding"), versus a net loss of $347,000, or $0.02 per share, on 23.0 million shares outstanding in the same prior year period.

Stellar's balance sheet at June 30, 2006 was highlighted by $1.3 million in cash and cash equivalents, $1.7 million in working capital and no long-term debt.

Conference Call

Management will conduct a conference call today at 11:00 a.m. Eastern Time to discuss these results. Interested parties may participate in the call by dialing 877-461-2814 (in the United States) or 416-695-9753 (in Canada) approximately 10 minutes before the call is scheduled to begin and ask to be connected to the Stellar Pharmaceuticals Conference Call.

About Stellar Pharmaceuticals Inc.

Stellar has developed and is marketing direct in Canada, and in countries around the world through out-license agreements, three products based on its core polysaccharide technology: NeoVisc®, for the treatment of osteoarthritis; and Uracyst® and the Uracyst® Test Kit, its patented technology for the diagnosis and treatment of interstitial cystitis (IC), an inflammatory disease of the urinary bladder wall. Stellar also has an in-licensing agreement for NMP22® BladderChek®, a proteomics-based diagnostic test for the diagnosis and monitoring of bladder cancer.

This press release contains forward-looking statements as defined in the Private Securities Litigation Reform Act of 1995. Readers are cautioned not to place undue reliance on these forward-looking statements. Actual results may differ materially from those indicated by these forward-looking statements as a result of risks and uncertainties impacting the Company's business including increased competition; the ability of the Company to expand its operations, to attract and retain qualified professionals, technological obsolescence; general economic conditions; and other risks detailed from time to time in the Company's filings.



Stellar Pharmaceuticals Inc.
Statement of Operations
(Canadian Funds; US GAAP)
(Unaudited)

For the Three For the Six
Month Period Month Period
Ended June 30 Ended June 30
2006 2005 2006 2005
---- ---- ---- ----

PRODUCT SALES $ 336,828 $ 421,459 $ 693,480 $ 780,914

COST OF GOODS SOLD 83,707 91,586 214,477 185,619
---------- ---------- ---------- ----------
MARGIN ON PRODUCT
SOLD 253,121 329,873 479,003 595,295

ROYALTY AND
LICENSING REVENUES 103,454 74,882 192,719 140,725
---------- --------- ---------- ---------

GROSS PROFIT 356,575 404,755 671,722 736,020
---------- --------- ---------- ---------
EXPENSES
Selling, general,
and administrative $ 493,368 $ 643,370 1,079,596 1,256,374
Research and
development 67,716 91,450 123,493 284,685
Amortization 38,954 34,681 78,351 67,682
---------- ---------- --------- ---------
600,038 769,501 1,281,440 1,608,741
---------- ---------- --------- ---------

LOSS FROM
OPERATIONS (243,463) (364,746) (609,718) (872,721)

INTEREST AND OTHER
INCOME 11,136 17,434 23,347 70,754
---------- ---------- --------- ----------

NET LOSS FOR THE
PERIOD (232,327) (347,312) (586,371) (801,967)

LOSS PER SHARE $ (0.01) $ (0.02) $ (0.02) $ (0.03)
---------- ---------- --------- ----------
---------- ---------- --------- ----------

WEIGHTED AVERAGE
NUMBER OF
COMMON SHARES
OUTSTANDING 23,494,283 23,159,131 23,483,367 23,089,571
---------- ---------- ---------- ----------
---------- ---------- ---------- ----------


Stellar Pharmaceuticals Inc.

Balance Sheets
(Canadian Funds; US GAAP)
ASSETS
As at As at
June 30, 2006 December 31, 2005
------------- -----------------
CURRENT (Unaudited) (Audited)

Cash and cash equivalents $ 1,300,245 $ 2,108,755
Accounts receivable 227,385 157,749
Inventories 281,731 288,337
Prepaid, deposits, and sundry
receivables 102,520 152,514
------------ ------------
1,911,881 2,707,355

PROPERTY, PLANT, AND EQUIPMENT 909,227 959,999

OTHER ASSETS 45,509 46,187
------------ ------------
$ 2,866,617 $ 3,713,541
------------ ------------
------------ ------------

LIABILITIES

CURRENT
Accounts payable $ 225,769 $ 487,359
Accrued liabilities 35,062 122,999
Deferred revenues - 43,397
------------ ------------
260,831 653,755
------------ ------------

SHAREHOLDERS' EQUITY

CAPITAL STOCK
AUTHORIZED
Unlimited Non-voting,
convertible,
redeemable, and
retractable
preferred
shares with no par
value
Unlimited Common shares with
no par value

ISSUED
23,622,690 Common shares
(2005 -- 23,470,190) 8,151,428 8,100,253
Paid-in capital
options
- outstanding 626,221 545,025
- expired 98,913 98,913
DEFICIT (6,270,776) (5,684,405)
----------- -----------
2,605,786 3,059,786
----------- -----------
$ 2,866,617 $ 3,713,541
----------- -----------
----------- -----------



The TSX Venture Exchange has not reviewed and does not accept responsibility for the adequacy or accuracy of this release.

Contact Information

  • Stellar Pharmaceuticals Inc.
    Peter Riehl
    President & CEO
    (800) 639-0643 or (519) 434-1540
    or
    Stellar Pharmaceuticals Inc.
    Arnold Tenney
    Cell (416) 587-3200
    or
    INVESTOR RELATIONS COUNSEL:
    The Equity Group Inc.
    Adam Prior
    (212) 836-9606
    aprior@equityny.com
    or
    The Equity Group Inc.
    Devin Sullivan
    (212) 836-9608
    dsullivan@equityny.com